Virnext offers several in vitro assays for screening antiviral candidates against a large panel of human and animal viral strains (See virus library), and accomplishes complete evaluation of the impact of your compounds, antibody or vaccine candidate at different levels of concentrations on various biological supports.
Different in vitro compound evaluation services are available, such as high throughput screening or complete evaluation and characterization of the antiviral or proviral effect of specific compounds, which can be evaluated on a large panel of viral strains according to the customer’s specific needs.
Virnext has developed cell line infection models about influenza virus, SARS-CoV-2, metapneumovirus and adenovirus. These models are fully characterized in terms of infectivity, viral kinetics and physiological integrity, and are used in routine in our BSL-2 and BSL-3 facilities.
Find below the different cell lines on which our in vitro infection models are based, including reporter viruses allowing not only to monitor infection at each time but also rapid and accurate luminescence and fluorescence measurements.
Influenza virus
SARS-CoV-2
RSV A / RSV B
HMPV A / HMPV B
